SCHEMBL2832640

SCHEMBL2832640

CNC(=O)[C@@H]1CC[C@H](c2ccc(OCc3ccccc3F)cc2)N1C(=O)O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 6/20 0.63
SCN3A Q9NY46 8/20 0.52
FFAR2 O15552 1/20 0.52
SCN9A Q15858 2/20 0.48
SCN1A P35498 1/20 0.48
SCN4A P35499 1/20 0.48
SCN7A Q01118 1/20 0.48
SCN5A Q14524 1/20 0.48
SCN2A Q99250 1/20 0.48
SCN8A Q9UQD0 1/20 0.48
SCN10A Q9Y5Y9 1/20 0.48
MAOB P27338 4/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2B6 P20813 1/20 0.47
CYP2C19 P33261 1/20 0.47
MMP1 P03956 3/20 0.44
ADAM17 P78536 2/20 0.44
KDM1A O60341 1/20 0.44
MAOA P21397 1/20 0.44
PARP15 Q460N3 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2837773 0.89 KCNH2 (0.66) KCNH2SCN3AFFAR2SCN9ASCN1A
SCHEMBL2835344 0.88 KCNH2 (0.77) KCNH2SCN3AFFAR2SCN9ASCN1A
SCHEMBL4712753 0.88 KCNH2 (0.58) KCNH2SCN3AFFAR2SCN9ASCN1A
SCHEMBL12206746 0.88 KCNH2 (0.58) KCNH2SCN3AFFAR2SCN9ASCN1A
Hydrochloric Acid SCHEMBL2837163 0.87 KCNH2 (0.76) KCNH2SCN3AFFAR2SCN9ASCN1A
SCHEMBL2712421 0.87 KCNH2 (0.76) KCNH2SCN3AFFAR2SCN9ASCN1A
SCHEMBL2714986 0.87 KCNH2 (0.76) KCNH2SCN3AFFAR2SCN9ASCN1A
SCHEMBL2712355 0.87 KCNH2 (0.76) KCNH2SCN3AFFAR2SCN9ASCN1A
SCHEMBL2831391 0.86 KCNH2 (0.63) KCNH2SCN3AFFAR2SCN9ASCN1A
SCHEMBL2717479 0.84 KCNH2 (0.62) KCNH2SCN3AFFAR2SCN9ASCN1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7855218-B2 (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide; depression or a mood disorder ; modulation of use-dependent voltage-gated sodium channels Convergence Pharmaceuticals Limited (GB) 2010-12-21 US disclosed
EP-1943216-B1 PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS GLAXO GROUP LTD (GB) 2010-06-30 EP disclosed
US-20080306122-A1 Novel Compounds Convergence Pharmaceuticals Limited (GB) 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306122-A1 Novel Compounds CYP11B1, CYP11B2, CYP46A1 KCNH2 3313/4885SCN3A 2352/4885FFAR2 1225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.